| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2015034820 |
| Title |
Compounds Useful As Immunomodulators. |
| Abstract |
Disclosed are compounds of Formula (I): (I). Also disclosed are methods of using such compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of virological diseases or disorders and cancer. |
| Applicant(s) |
Bristol-Myers Squibb Company |
| Representative Drug(s) |
D0OK1S |
Drug Info
|
IC50 = 150 nM |
[1] |
| Patent ID |
WO2015195163 |
| Title |
Pd-L1 Antagonist Fully Human Antibody. |
| Abstract |
A antibody is described that can be used for treating or prevention of an immunological or an oncological disease or condition. The antibody is a fully human single-chain variable fragment (scFv) antibody molecule which is capable of binding to human PDl receptor and inhibiting its interactions with its cognate ligand - human PD- Ll. DNA expression vectors and expression systems for overproducing the antibody in mammalian cells are also provided for. |
| Applicant(s) |
R-Pharm Overseas, Inc |
| Patent ID |
WO2015181342 |
| Title |
Pd-L1 Antibodies and Uses Thereof. |
| Abstract |
Provided herein are PD-L1 antibodies and methods for using the same for diagnosing a medical condition associated with elevated PD-L1 levels (e.g., cancer) in subjects in need thereof. PD-L1 antibodies are also useful in evaluating the efficacy of a particular therapeutic regime in a subject diagnosed as having a PD-L1-related medical condition. |
| Applicant(s) |
Spring Bioscience Corporation |
| Patent ID |
WO2015112805 |
| Title |
Human Antibodies To Pd-L1. |
| Abstract |
The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligandl (PD-L1 ) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection. |
| Applicant(s) |
Regeneron Pharmaceuticals, Inc |
| Patent ID |
WO2015103602 |
| Title |
Pd1 and Pdl1 Antibodies and Vaccine Combinations and Use of Same for Immunotherapy. |
| Abstract |
Disclosed herein is a vaccine comprising an antigen and PD1 antibody and/or PDL1 antibody. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof. |
| Applicant(s) |
The Trustes of the University of Pennsylvania |
| Patent ID |
WO2014100079 |
| Title |
Antibodies That Bind To Human Programmed Death Ligand 1 (Pd-L1). |
| Abstract |
The present disclosure provides isolated antibodies that specifically bind to human PD-L1, as well as antigen binding fragments of such antibodies, and kits comprising the anti-PD-L1 antibodies or binding fragments and a set of reagents for detecting a complex of the antibody, or antigen binding fragment thereof, bound to human PD-L1. The antibodies and antigen binding fragments of this disclosure are useful for immunohistochemical detection of human PD-L1 expression in tissue samples. Nucleic acid molecules encoding the antibodies and antigen binding fragments of this disclosure, as well as expression vectors and host cells for expression thereof, are also provided. |
| Applicant(s) |
Merck Sharp & Dohme Corp |
| Patent ID |
WO2014055897 |
| Title |
Human Monoclonal Anti-Pd-L1 Antibodies and Methods of Use. |
| Abstract |
The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections. |
| Applicant(s) |
Dana-Farber Cancer Institute, Inc |
| Patent ID |
WO2013181452 |
| Title |
Methods of Treating Cancer Using Pd-L1 Axis Binding Antagonists and Vegf Antagonists. |
| Abstract |
The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. |
| Applicant(s) |
Genentech, Inc |
| Patent ID |
WO2012145493 |
| Title |
Antibodies and Other Molecules That Bind B7-H1 and Pd-1. |
| Abstract |
The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases. |
| Applicant(s) |
Amplimmune, Inc |
| Patent ID |
WO2010089411 |
| Title |
Pd-1 Antibodies and Pd-L1 Antibodies and Uses Thereof. |
| Abstract |
The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof. |
| Applicant(s) |
Inserm (Institut National De La Sante et De La Recherche Medicale) |
| Patent ID |
WO2010036959 |
| Title |
Human Anti-Pd-1, Pd-L1, and Pd-L2 Antibodies and Uses Therefor. |
| Abstract |
The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein. |
| Applicant(s) |
Dana-Farber Cancer Institute, Inc |
